The drugs group had high hopes for its anti-obesity drug, but as diet pills have fallen from favour so have its shares Robert Lindsay: Small caps Alizyme, the pharmaceutical group whose share price grew fat on hopes for an anti-obesity drug, suffered a...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Change in climate fails to suit Alizyme
Please enter your email address and password. Not a member? Join now
